Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00267254 | A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol. | PHASE3 | COMPLETED | 640 | — | — | Jan 1, 2006 | Aug 1, 2006 | Nov 21, 2007 | 49 | United States |
| NCT00139061 | Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate | PHASE3 | COMPLETED | 128 | — | — | Mar 1, 2005 | May 1, 2006 | Oct 31, 2007 | 26 | France |
| NCT00137462 | Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone. | PHASE3 | COMPLETED | 900 | — | — | Nov 1, 2004 | Sep 1, 2006 | Nov 16, 2007 | 59 | United States, Canada |
| NCT00138762 | A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol | PHASE3 | COMPLETED | 3,800 | — | — | Jul 1, 2004 | Aug 1, 2006 | Feb 17, 2012 | 154 | United States, Belgium +6 |
| Name | Type | Description |
|---|---|---|
| torcetrapib/atorvastatin | DRUG | - |
| simvastatin | DRUG | - |
| Fenofibrate | DRUG | - |
| atorvastatin | DRUG | - |
| placebo | DRUG | - |
Inclusion Criteria: * eligible for statin treatment for LDL cholesterol by NCEP guidelines Exclusion Criteria: * Women who are pregnant or lactating, or planning to become pregnant. * Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA r...